New drug cocktail aims to keep relapsed myeloma in check

NCT ID NCT03030261

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II study tests whether a combination of elotuzumab, pomalidomide, and dexamethasone can help control relapsed multiple myeloma after a second stem cell transplant. The trial enrolls 25 adults whose myeloma returned after their first transplant. Participants receive the drug combo as maintenance therapy to delay further relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elotuzumab, pomalidomide, and dexamethasone
What this could lead to: If successful, this combination therapy could improve control of relapsed multiple myeloma and extend the time before the disease progresses again.
What could go wrong: This is a small, early-phase study with only 25 participants, so results may not apply to everyone. The drugs can cause side effects like low blood counts, infections, and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA IN RELAPSE

Contacts and locations

Locations

Colorado Blood Cancer Institute (Sarah Cannon)

Denver, Colorado, 80218, United States
University Health Network - Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.